Development of an evaluation and treatment strategy for olfactory neuroblastoma: a review of evidence from large-scale studies, including population-based and multicenter studies, and meta-analyses
Japanese Journal of Clinical Oncology · 14.08.2024 · 54 (8) · 847-862
DOI: 10.1093/jjco/hyae062 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Japanese Journal of Clinical Oncology, online erschienen am 18.05.2024. Verfasst von Yosuke Ariizumi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Surgery, Tokyo Medical and Dental University, Tokyo, Japan. Hauptthemen laut MEDLINE: Esthesioneuroblastoma, Olfactory, Nasal Cavity, Nose Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 141 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Olfactory neuroblastoma is a rare sinonasal malignancy arising from the olfactory epithelium that is characterized by skull base involvement and a modest natural history. Because of its rarity and long course, identification of independent prognostic factors is dependent on multivariate analysis of large, long-term data. In this review, we outline evidence for the evaluation and treatment of olfactory neuroblastoma obtained from recent large-scale population-based studies, meta-analyses and multicenter studies. Hyams grade is currently the only pathological grade system for olfactory neuroblastoma. The modified Kadish staging and Dulguerov classification are available for clinical staging. The results of large-scale studies have confirmed Hyams, the modified Kadish and Dulguerov as independent prognostic factors. Surgery followed by radiotherapy provides the best overall survival and recurrence-free survival for resectable disease. The question of whether postoperative radiotherapy should be administered for all cases or only for those at risk of recurrence remains unanswered. Exclusively endoscopic resection is indicated for modified Kadish A/B cases without any increase in the risk of death or recurrence, and is also indicated for modified Kadish C cases if a negative surgical margin is ensured. For more advanced cases, such as those with extensive brain infiltration, the open approach is indicated. Elective nodal irradiation prevents late nodal recurrence of N0 patients. Chemotherapy has failed to show a benefit in survival or disease control. Current needs for olfactory neuroblastoma include the development and validation of refined staging systems suitable for current practice; expansion of indications for endoscopic surgery; less invasive surgery; definitive radiotherapy and novel systemic therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Head and Neck Surgery, Tokyo Medical and Dental University, Tokyo, Japan.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Ariizumi, Y., & Asakage, T. (2024). Development of an evaluation and treatment strategy for olfactory neuroblastoma: a review of evidence from large-scale studies, including population-based and multicenter studies, and meta-analyses. Japanese Journal of Clinical Oncology, 54(8), 847-862. https://doi.org/10.1093/jjco/hyae062
Vancouver
Ariizumi Y, Asakage T. Development of an evaluation and treatment strategy for olfactory neuroblastoma: a review of evidence from large-scale studies, including population-based and multicenter studies, and meta-analyses. Japanese Journal of Clinical Oncology. 2024;54(8):847-862. doi:10.1093/jjco/hyae062
BibTeX
@article{Ariizumi2024,
author = {Ariizumi, Yosuke and Asakage, Takahiro},
title = {Development of an evaluation and treatment strategy for olfactory neuroblastoma: a review of evidence from large-scale studies, including population-based and multicenter studies, and meta-analyses},
journal = {Japanese Journal of Clinical Oncology},
year = {2024},
volume = {54},
number = {8},
pages = {847--862},
doi = {10.1093/jjco/hyae062}
}
EUVIMED